DAYBUE STIX Receives FDA Clearance: New Treatment Option for Rett Syndrome Patients

Acadia Pharmaceuticals has secured U.S. FDA authorization for DAYBUE STIX, introducing a powder formulation alternative to its existing oral solution for managing Rett syndrome in pediatric and adolescent patients age two and above. This rare genetic neurodevelopmental condition affects roughly 1 in 10,000 to 15,000 female births globally.

The newly cleared powder form maintains identical efficacy and safety characteristics as the liquid DAYBUE formulation that received FDA approval in 2023. The company indicated that DAYBUE STIX will initially launch with restricted distribution beginning Q1 2026, followed by expanded market access anticipated for early Q2 2026, while the original solution remains in circulation for existing patients.

Rett syndrome adalah a progressive neurological disorder primarily impacting girls, characterized by normal early development followed by regression in motor control, communication, and cognitive abilities. The introduction of DAYBUE STIX offers patients and caregivers an additional administration route, potentially improving treatment compliance and quality of life for those managing this debilitating condition.

This regulatory milestone underscores continued pharmaceutical innovation targeting rare pediatric neurological disorders, providing clinicians with diverse treatment delivery options to better serve vulnerable patient populations.